American Association for Cancer Research
Browse
00085472can110076-sup-stab_1_xls_file_-__26k.xls (26.5 kB)

Supplementary Table 1 from Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase Targets

Download (26.5 kB)
dataset
posted on 2023-03-30, 20:21 authored by Yan Ding, Dan Huang, Zhongfa Zhang, Josh Smith, David Petillo, Brendan D. Looyenga, Kristin Feenstra, Jeffrey P. MacKeigan, Kyle A. Furge, Bin T. Teh

XLS file - 26K

History

ARTICLE ABSTRACT

In recent years, several molecularly targeted therapies have been approved for clear cell renal cell carcinoma (ccRCC), a highly aggressive cancer. Although these therapies significantly extend overall survival, nearly all patients with advanced ccRCC eventually succumb to the disease. To identify other molecular targets, we profiled gene expression in 90 ccRCC patient specimens for which tumor grade information was available. Gene set enrichment analysis indicated that cell-cycle–related genes, in particular, Polo-like kinase 1 (PLK1), were associated with disease aggressiveness. We also carried out RNAi screening to identify kinases and phosphatases that when inhibited could prevent cell proliferation. As expected, RNAi-mediated knockdown of PLK1 and other cell-cycle kinases was sufficient to suppress ccRCC cell proliferation. The association of PLK1 in both disease aggression and in vitro growth prompted us to examine the effects of a small-molecule inhibitor of PLK1, BI 2536, in ccRCC cell lines. BI 2536 inhibited the proliferation of ccRCC cell lines at concentrations required to inhibit PLK1 kinase activity, and sustained inhibition of PLK1 by BI 2536 led to dramatic regression of ccRCC xenograft tumors in vivo. Taken together, these findings highlight PLK1 as a rational therapeutic target for ccRCC. Cancer Res; 71(15); 5225–34. ©2011 AACR.